New Endocrine Treatments for Prostate Cancer

Publication
Article
OncologyONCOLOGY Vol 11 No 12
Volume 11
Issue 12

New treatments announced at the 1997 Endocrine Society Annual Meeting could help slow the rate of prostate cancer growth and improve the quality of life of those who have the disease.

New treatments announced at the 1997 Endocrine Society Annual Meeting could help slow the rate of prostate cancer growth and improve the quality of life of those who have the disease.

Coleman Gross, MD, of Stanford University School of Medicine, reported on a study of the effect of high doses of calcitriol, the active form of vitamin D, on prostate cancer patients. Calcitriol was administered to men who had recurrent disease after surgery or radiation. Calcitriol appeared to lessen the rate of increase of prostate-specific antigen (PSA), suggesting that the rate of prostate cancer growth was slowed. These results suggest that calcitriol and related drugs may have a future role in the treatment of early-stage prostate cancer.

Marina Cesana, MD, of Mediolanum Farmaceutici in Milan, Italy, discussed a study of avorelin in the treatment of prostate cancer patients. In the study, avorelin was given through a subcutaneous implant to patients with untreated prostate cancer. The results indicated that the drug acted as a potent antiandrogen, keeping testosterone levels suppressed for 6 to 7 months. 

Recent Videos
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr., MD.
Related Content